There is emerging evidence from in vivo and in vitro experiments that suggests that PDE5 inhibitors have anticancer effects in many types of cancers, such as chronic lymphocytic leukemia, prostate, colorectal, brain, breast, and lung cancers [11,12,13,14]. The gene discussed is PDE5A; the disease is cancer.